Predictive Technology Group, Inc. (PREDQ)
0.0000
0.00 (0.00%)
USD |
OTCM |
Feb 20, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.003M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 900.0% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 100.0% |
Profile
| Predictive Technology Group, Inc. engages in the development and commercialization of discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic and human cells, tissues, and human cellular and tissue-based products. It operates through the Human Cell and Tissues Products (HCT/P), and Diagnostics and Therapeutics segments. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors, and cytokines. The Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. The company was founded in 2005 and is headquartered in Salt Lake City, UT. |
| URL | http://www.predtechgroup.com |
| Investor Relations URL | N/A |
| HQ State/Province | Utah |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 16, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Predictive Technology Group, Inc. engages in the development and commercialization of discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic and human cells, tissues, and human cellular and tissue-based products. It operates through the Human Cell and Tissues Products (HCT/P), and Diagnostics and Therapeutics segments. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors, and cytokines. The Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. The company was founded in 2005 and is headquartered in Salt Lake City, UT. |
| URL | http://www.predtechgroup.com |
| Investor Relations URL | N/A |
| HQ State/Province | Utah |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 16, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |